# Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE  

Single Technology Appraisal  
Ivabradine for the treatment of chronic heart failure  

Matrix of consultees and commentators

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
</table>
| **Manufacturers/sponsors**  
- Servier Laboratories (ivabradine) | **General**  
- Board of Community Health Councils in Wales  
- British Cardiovascular Industry Association  
- British National Formulary  
- Care Quality Commission  
- Commissioning Support Appraisals Service  
- Department of Health, Social Services and Public Safety for Northern Ireland  
- Health Care Improvement Scotland  
- Medicines and Healthcare products Regulatory Agency  
- National Association of Primary Care  
- NHS Alliance  
- NHS Commercial Medicines Unit  
- NHS Confederation  
- Public Health Wales NHS Trust  
- Scottish Medicines Consortium |
| **Patient/carer groups**  
- Action Heart  
- Afiya Trust  
- Black Health Agency  
- Blood Pressure Association  
- British Cardiac Patients Association  
- Cardiac Risk in the Young (CRY)  
- Cardiomyopathy Association  
- Counsel and Care  
- Equalities National Council  
- Grown Up Congenital Heart Patients Association  
- Heart Care Partnership (UK)  
- HEART UK  
- Muslim Council of Britain  
- Muslim Health Network  
- Network of Sikh Organisation  
- South Asian Health Foundation  
- Specialised Healthcare Alliance |  
| **Professional groups**  
- British Association of Emergency Medicine  
- British Association for Nursing in Cardiac Care  
- British Association for Service to the Elderly  
- British Atherosclerosis Society  
- British Cardiovascular Intervention Society (BCIS)  
- British Cardiovascular Society  
- British Geriatrics Society  
- British Heart Foundation |  
| **Possible comparator manufacturers**  
- Abbott Healthcare Products (eprosartan)  
- Actavis UK (spironolactone, losartan, hydralazine, isosorbide dinitrate, valsartan)  
- Amdipharm (hydralazine, losartan)  
- Arrow Generics (losartan)  
- Boehringer Ingelheim (telmisartan)  
- Bristol-Myers Squibb (irbesartan)  
- Consilient Health (losartan, valsartan)  
- Daiichi Sankyo UK (olmesartan medoxomil)  
- Dexcel Pharma (losartan. isosorbide dinitrate, valsartan) |
### Consultees
- British Nuclear Cardiology Society
- British Society for Heart Failure
- Heart Rhythm UK
- National Heart Forum (UK)
- National Pharmacy Association
- Primary Care Cardiovascular Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiological Science & Technology
- United Kingdom Clinical Pharmacy Association
- Vascular Society

### Others
- Department of Health
- NHS Central and Eastern Cheshire
- NHS Devon
- Welsh Government

### Commentators (no right to submit or appeal)
- Dr Reddy’s Laboratories (spironolactone, losartan)
- Essential Generics (isosorbide dinitrate)
- Goldshield Critical Care (isosorbide dinitrate)
- Kent Pharmaceuticals (spironolactone, losartan)
- Merck Sharp & Dohme (losartan)
- Metwest Pharmaceuticals (spironolactone)
- Milpharm (isosorbide dinitrate)
- Mylan (losartan, hydralazine, isosorbide dinitrate)
- Novartis Pharmaceuticals (valsartan)
- Pfizer (losartan, eplerenone, spironolactone, isosorbide dinitrate)
- Ranbaxy UK (losartan)
- Ratiopharm UK (losartan)
- Sandoz UK (losartan, isosorbide dinitrate)
- sanofi (spironolactone, irbesartan)
- Takeda UK (candesartan cilexetil)
- Teva UK (spironolactone, losartan, isosorbide dinitrate, valsartan)
- UCB Pharma (isosorbide dinitrate)
- Zentiva (losartan, valsartan)

### Relevant research groups
- British Society for Cardiovascular Research [BCS affiliated]
- Cardiac and Cardiology Research Dept, Barts
- Cardiovascular Diseases Specialist Library (CVDSL)
- Cardiovascular Research Initiative, University of Oxford
- Central Cardiac Audit Database
- Cochrane Heart Group
- CORDA
- European Council for Cardiovascular Research
- MRC Clinical Trials Unit
- National Heart Research Fund
- National Institute for Health Research
- Research Institute for the Care of Older
## Appendix C

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>People</td>
<td>People</td>
</tr>
<tr>
<td></td>
<td>• Wellcome Trust - Cardiovascular Research Initiative</td>
</tr>
<tr>
<td>Evidence Review Group</td>
<td>Evidence Review Group</td>
</tr>
<tr>
<td></td>
<td>• BMJ Evidence Centre</td>
</tr>
<tr>
<td></td>
<td>• National Institute for Health Research Health Technology Assessment Programme</td>
</tr>
<tr>
<td>Associated Guideline Groups</td>
<td>Associated Guideline Groups</td>
</tr>
<tr>
<td></td>
<td>• National Clinical Guidelines Centre</td>
</tr>
<tr>
<td>Associated Public Health Groups</td>
<td>Associated Public Health Groups</td>
</tr>
<tr>
<td></td>
<td>• tbc</td>
</tr>
</tbody>
</table>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

**Definitions:**

**Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).
All non-manufacturer/sponsor consultees are invited to submit a statement\(^1\), respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

**Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

**Evidence Review Group (ERG)**

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

\(^1\) Non manufacturer consultees are invited to submit statements relevant to the group they are representing.